Nektar sues Lilly, claiming its interest in biotech’s autoimmune drug ‘waned dramatically’ after buying DermiraDermira

Nektar Therapeutics is taking Eli Lilly to court in California, saying the Indianapolis-based drugmaker mishandled data and “executed on a scheme to ensure that REZPEG would never succeed” after it bought another autoimmune drug candidate.

The lawsuit was filed in the US District Court for the Northern District of California on Monday, the same day the San Francisco biotech said Lilly miscalculated data in an eczema trial. Lilly axed their six-year, $400 million pact for the investigational drug, known as rezpegaldesleukin, or rezpeg, in April.

Preview

来源: EndPoints

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP

LOG IN

BECOME A PREMIUM SUBSCRIBER

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。